LIDDS AB (publ) announced that the Board of Directors has appointed the drug delivery company's CFO Jenni Björnulfson as the new CEO. She succeeds Matthew Lindon, who has been acting CEO of LIDDS since July 2023, and who is scheduled to leave the company at the end of the year. Jenni Björnulfson will take up the position as CEO on December 1, 2023.

Matthew Lindon has held the role of CSO of LIDDS since March 2022. In July 2023, he was appointed acting CEO after former CEO Anders Månsson announced that he was leaving his position. Jenni Björnulfson will continue in the role of CFO in parallel with her new position.

Jenni Björnulfson (born 1971) has been CFO of LIDDS AB since 2021. Jenni has a solid background in finance and from the biotech sector, including being CFO of Promore Pharma and Cinclus Pharma. Jenni has also been an equity analyst at ABG Sundal Collier and worked with corporate finance at Alfred Berg and Handelsbanken.

Jenni holds a master's degree in economics from the Stockholm School of Economics and has also studied at Karolinska Institutet.